Eiger Mountains
Keyword Search
 
2017 | 2016
DateTitle 
03/23/17Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results
- Five Phase 2 Programs in Four Orphan Indications - Multiple Value-Creating Events Across Programs Expected in Next 12-18 Months PALO ALTO, Calif., March 23, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today a business update and financial results for the three months and full year ended December 31, 2016. "We believe that 2016, Eiger's first year as a publ... 
Printer Friendly Version
01/30/17Eiger BioPharmaceuticals to Present at BIO CEO & Investor Conference February 13th and Participate in SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th
PALO ALTO, Calif., Jan. 30, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at the 19th Annual BIO CEO & Investor Conference at 10:00 am ET on Monday, February 13, 2017, at the Waldorf Astoria Hotel in New York City.  A live webcast ... 
Printer Friendly Version
01/04/17Eiger Completes $25 Million Debt Financing with Oxford Finance
PALO ALTO, Calif., Jan. 4, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, today announced that it has completed a $25 million debt financing transaction with Oxford Finance LLC ("Oxford"), a specialty finance firm that provides senior debt to life sciences and healthcare services companies worldwide.  Proceeds of the financing are intended for use to advance Eiger's diverse pipeline of clinical ... 
Printer Friendly Version
01/03/17Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension (PAH)
First-in-class inhibitor of LTB4 targeting disease modification in PAH PALO ALTO, Calif., Jan. 3, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, today announced that the first patient has completed 24 weeks dosing in the double-blind Phase 2 LIBERTY study and has now received treatment with ubenimex in the open-label extension. LIBERTY is a randomized, double-blind, placebo-controlled study ... 
Printer Friendly Version